Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: A pilot study

Veterinary Dermatology

Volumn 13, Issue 4, 2002, Pages 203-210

  Marsella, Rosanna ^a,b   Nicklin, Constance F ^a  

^a University of Florida College of Veterinary Medicine   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Atopic dermatitis; Canine; FK 506; Tacrolimus

Indexed keywords

CANIS FAMILIARIS;

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ANIMAL; ANIMAL DISEASE; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; INTRADERMAL DRUG ADMINISTRATION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANIMALS; DERMATITIS, ATOPIC; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; IMMUNOSUPPRESSIVE AGENTS; PILOT PROJECTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0036672940     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3164.2002.00299.x     Document Type: Article

References (37)

1. Scott, D.W., Miller, W.H., Griffin, C.E. Small Animal Dermatology 6th edn. Philadelphia: WB Saunders, 2001: 574-601.
2. Olivry, T., Rivierre, C., Jackson, H.A., et al. Cyclosporin-A decreases skin lesions and pruritus in dogs with atopic dermatitis: a prednisolone-controlled blinded trial. Veterinary Dermatology 2000; 11: 47.
3. Haslam, N., Hearing, S.D., Probert, C.S. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. European Journal of Gastroenterology and Hepatology 2000; 12: 657-60.
4. Kino, T., Hatanaka, H., Hashimoto, M., et al. FK-506, a novel immunosuppressant isolated from Streptomyces I. Fermentation, isolation, physico-chemical and biological characteristics. Journal of Antibiotics 1987; 40: 1249-55.
5. Schreiber, S.L., Crabtree, G.R. The mechanism of action of cyclosporine A and FK-506. Immunology Today 1992; 12: 136-42.
6. Sakuma, S., Higashi, Y., Sato, N., et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). International Immunopharmacology 2001; 1: 1219-26.
7. de Paulis, A., Stellato, C., Cirillo, R., Oriente, A., Marone, G. Anti-inflammatory effect of FK-506 on human skin mast cells. Journal of Investigative Dermatology 1992; 99: 723-8.
8. Thomson, A.W., Nalesnik, M., Abu-Elmagd, K., Starzl, T.E. The influence of FK-506 on T lymphocytes, Langerhans' cells, and the expression of cytokine receptors and adhesion molecules in psoriatic skin: a preliminary study. Transplantation Proceedings 1991; 23: 3330-1.
9. Thomson, A.W., Nalesnik, M., Abu-Elmagd, K., Starzl, T.E. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. Transplantation Proceedings 1991; 23: 3330-1.
10. Wollenberg, A., Sharma, S., von Bubnoff, D., Geiger, E., Haberstok, J., Bieber, T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. Journal of Allergy and Clinical Immunology 2001; 107: 519-25.
11. Panhans-Gross, A., Novak, N., Kraft, S., Bieber, T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). Journal of Allergy and Clinical Immunology 2001; 107: 345-52.
12. Meingassner, J.G., Stutz, A. Immunosuppressive macrolides of the type FK-506: a novel class of topical agents for the treatment of skin diseases? Journal of Investigative Dermatology 1992; 98: 851-5.
13. Lauema, A.I., Surber, C., Maibach, H.I. Absorption of topical tacrolimus (FK-506) in vitro through human kin: comparison with Cyclosporine A. Skin Pharmacology 1997; 10: 230-4.
14. Aoyama, H., Tabata, N., Tanaka, M., Uesugi, Y., Tagami, H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK-506 ointment. British Journal of Dermatology 1995; 133: 494-6.
15. Nakagawa, H., Etoh, T., Ishibashi, Y. et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883.
16. Paller, A., Eichenfield, L.F., Leung, D.Y.M., Stewart, D., Appell, M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology 2001; 44: S47-57.
17. Hanifin, J.M., Ling, M.R., Langley, R., Breneman, D., Rafal, E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, Efficacy. Journal of the American Academy of Dermatology 2001; 44(Suppl.): 28-38.
18. Boguniewicz, M., Fiedler, V.C., Raimer, S., Lawrence, I.D., Leung, D.Y., Hanifin, J.M. A randomized, vehicle controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Journal of Allergy and Clinical Immunology 1998; 102: 637-44.
19. Alaiti, S., Kang, S., Fiedler, V.C. et al. Tacrolimus (FK-506) ointment for atopic dermatitis. A phase I study in adults and children. Journal of the American Academy of Dermatology 1998; 38: 69-76.
20. Kershner, R.P., Fitzsimmons, WE. Relationship of FK-506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-6.
21. Soter, N.A., Fleisher, A.B., Webster, G.F., Monroe, E., Lawrence, I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety. Journal of the American Academy of Dermatology 2001; 44(Suppl.): 39-46.
22. Bieber, T. Topical tacrolimus: a new milestone in the management of atopic dermatitis. Journal of Allergy and Clinical Immunology 1998; 102: 555-7.
23. Morimoto, T., Yamada, F., Kobayashi, T. et al. Blood levels of FK-506 after intramuscular and intravenous administration in dogs. Transplantation Proceedings 1989; 21: 1059-63.
24. Furukawa, H., Imventarza, O., Venkataramanan, R. et al. The effect of bile duct ligation and bile diversion on FK-506 pharmacokinetics in dogs. Transplantation 1992; 53: 722-5.
25. Fukuse, T., Hasegawa, S., Hirai, T. et al. Optimal dose of FK-506 in canine lung allotransplantation. Transplantation Proceedings 1992; 24: 1399-400.
26. Zhu, Y., Suzuki, T., Subbotin, V.M. et al. Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents. Transplantation Proceedings 1997; 29: 308-9.
27. Fujisawa, T., Saitoh, Y., Urabe, N. et al. Dose study of the immunosuppression of FK-506 in canine lung allo-transplantation. Surgery Today 1993; 23: 338-43.
28. Marsella, R., Nicklin, C.F. Double blind placebo-controlled, crossover clinical trial on the efficacy of pentoxifylline in canine atopy. Veterinary Dermatology 2000; 11: 255-60.
29. Alak, A.M., Cook, M., Bekersky, I. A highly sensitive enzyme linked immunosorbent assay for the determination of tacrolimus in atopic dermatitis patients. Therapeutic Drug Monitoring 1997; 19: 88-91.
30. Nagase, K., Iwasaki, K., Nozaki, K., Noda, K. Distribution and protein binding of FK-506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. Journal of Pharmacy and Pharmacology 1994; 46: 113-7.
31. Olivry, T., Dean, G.A., Tompkins, M.B., Dow, J.L., Moore, P.F. Toward a canine model of atopic dermatitis: amplification of cytokine-gene transcripts in the skin of atopic dogs. Experimental Dermatology 1999; 8: 204-11.
32. Sinke, J.D., Thepen, T., Bihari, I.C., Rutten, V.P., Willemse, T. Immunophenotyping of skin-infiltrating T-cell subsets in dogs with atopic dermatitis. Veterinary Immunology and Immunopathology 1997; 57: 13-23.
33. Olivry, T., Moore, P.F., Affolter, V.K., Naydan, D.K. Langerhans cell hyperplasia and IgE expression in canine atopic dermatitis. Archives of Dermatological Research 1996; 288: 579-85.
34. Fontaine, J., Olivry, T. Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study. Veterinary Record 2001; 148: 662-3.
35. Winkler, M., Christians, U., Baumann, J., Gonschior, A.K., Wonigeit, K., Pichlmayr, R. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation. Therapeutic Drug Monitoring 1996; 18: 640-6.
36. MacFarlane, G.D., Venkataramanan, R., McDiarmid, S.V. et al. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. Pediatric Transplantation 2001; 5: 119-24.
37. MacFarlane, G.D., Scheller, D.G., Ersfeld, D.L. et al. Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood. Clinical Chemistry 1999, 2001; 45: 1449-58.